Hypopharyngeal Cancer Pipeline Review, H2 2012


#146103

50pages

Global Markets Direct

$ 2000

In Stock


Hypopharyngeal Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Hypopharyngeal Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypopharyngeal Cancer. Hypopharyngeal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hypopharyngeal Cancer.
  • A review of the Hypopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypopharyngeal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hypopharyngeal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypopharyngeal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypopharyngeal Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hypopharyngeal Cancer 7
Hypopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Hypopharyngeal Cancer Therapeutics Products under Investigation by Universities/Institutes 13
Assessment by Combination Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Radiation Therapy + Cetuximab - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 26
TS-1 + Nedaplatin + Radiation Therapy - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
S-1 + Radiation Therapy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
S-1 + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Docetaxel + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cisplatin + 5FU + Taxotere - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Lapatinib Ditosylate + Capecitabine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Erbitux + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
Hypopharyngeal Cancer Therapeutics Drug Profile Updates 46
Hypopharyngeal Cancer Therapeutics Discontinued Products 47
Hypopharyngeal Cancer Therapeutics - Dormant Products 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

Number of Products Under Development for Hypopharyngeal Cancer, H2 2012 7
Products under Development for Hypopharyngeal Cancer Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Assessment by Combination Products, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 18
Hypopharyngeal Cancer Therapeutics Drug Profile Updates 46
Hypopharyngeal Cancer Therapeutics Discontinued Products 47
Hypopharyngeal Cancer Therapeutics Dormant Products 48
Number of Products under Development for Hypopharyngeal Cancer, H2 2012 7
Products under Development for Hypopharyngeal Cancer Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Combination Products, H2 2012 14
Assessment by Route of Administration, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Molecule Type, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 18